Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular 5-Azacytidine for Recurrent Posterior Fossa Ependymoma
NCT02940483Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Feb 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in ependymoma, sponsored by UTHealth Houston. Primary endpoint: Number of patients with grade 3 through grade 5 new neurological adverse events at 4 months. Started Feb 2017; status: completed.
02
Drugs
azacitidine
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT02940483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940483.